Diaxonhit to launch its first proprietary product with BJI InoPlex CE marking
​Diaxonhit announced last November, positive results for the BJI InoPlex validation study, intended for the diagnosis of prosthetic joint infections (PJI). There are more than 3 million total hip and knee replacements performed every year in Europe and the US and this number is expected to grow with aging populations. As much as 20% of patients complain of pain following surgery. It is therefore crucial to identify early if it originates from PJI, an uncommon but serious complication. Bacterial infections can lead to bone damage and eventually to the removal or revision of the prosthesis. If detected early, current therapeutic procedures are 60% to 70% efficient in curing infections without replacement of the prosthesis. CE marking with BJI InoPlex allows Diaxonhit to market this rapid non-invasive diagnostic test for PJI, as early as Q1-2015.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.